The low-dose combined oral contraceptive containing 3-mg drospirenone/20-microgram ethinyl estradiol administered in a 24/4 regimen significantly reduced acne lesion counts more effectively than placebo and demonstrated greater improvement in the Investigator Static Global Assessment rating of acne. The safety profile was consistent with low-dose combined oral contraceptive use.
No takes yet. Share an insight, caveat, or question.
Maloney et al. (2008) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: